Filing Flows › Comparisons › ALLO vs VYGR
Allogene Therapeutics vs Voyager Therapeutics: ALLO and VYGR compared
Allogene Therapeutics is the larger company: $4.6M of revenue in its latest quarter (Q2 2026) against $4.0M for Voyager Therapeutics (Q3 2026).
Where the money goes: ALLO and VYGR
Allogene Therapeutics (ALLO) · Q2 2026
Allogene Therapeutics, Q2 2026: revenue $4.6M, net loss $42.7M, operating cash flow −$32.0M. The chart follows the revenue to costs, profit and cash.
Voyager Therapeutics (VYGR) · Q3 2026
Voyager Therapeutics, Q3 2026: revenue $4.0M (-70% year over year), operating margin -658.2%, net loss $24.7M, operating cash flow −$19.7M. The chart follows the revenue to costs, profit and cash.
| Allogene Therapeutics (ALLO) | Voyager Therapeutics (VYGR) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q3 2026 |
| Revenue | $4.6M | $4.0M |
| Revenue growth, Y/Y | — | -70% |
| Operating margin | n/m | -658.2% |
| Net earnings | −$42.7M | −$24.7M |
| Net margin | -919.8% | -615.2% |
| Operating cash flow | −$32.0M | −$19.7M |
Questions
Which is bigger, Allogene Therapeutics or Voyager Therapeutics?
Allogene Therapeutics is the larger company: $4.6M of revenue in its latest quarter (Q2 2026) against $4.0M for Voyager Therapeutics (Q3 2026).
More: Allogene Therapeutics earnings · how Allogene Therapeutics makes money · Voyager Therapeutics earnings · how Voyager Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 12, 2026; 10-Q filed Nov 5, 2026). Fiscal quarters can end on different dates. Not investment advice.